This research is a continuation of a usability study with the MARVIN chatbot. The investigators aim to adapt the MARVIN chatbot to open it to other health domains (e.g. breast cancer) and populations (e.g. pharmacists). Therefore, this protocol constitutes a master research protocol that will englobe different research projects with individual chatbots. The investigators adopt an adaptive platform trial design, which will allow flexibility in handling multiple interventions adapted to different populations while retaining the characteristics of a platform trial design allowing early withdrawal of ineffective trial arms based on interim data (implementation outcomes) and introduction of new trial arms.
being 14 years or older;
being fluent in English and/or French;
being able to understand the requirements of study participation and provide informed consent during the duration of the study;
having access to a smartphone, tablet, or computer at home/at workplace;
not meeting the inclusion criteria
any reason, in the opinion of the investigator, which would make the candidate inappropriate for participation in an investigative study involving a chatbot (e.g., cognitive deficit)
McGill University Health Centre/Research Institute of the McGill University Health Centre
Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Collaborator